Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6819670 | 0.86 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL5057478 | 0.84 | MEN1 (0.70) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL19549140 | 0.83 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL989637 | 0.80 | CA3 (0.63) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL7599922 | 0.78 | LMNA (0.39) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL13861685 | 0.78 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL9030133 | 0.78 | CA3 (0.60) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL236402 | 0.77 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL499036 | 0.75 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL22856384 | 0.74 | EPHX1 (0.37) | ALDH1A1SMN1; SMN2KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3207992-A1 | PHOTOCHEMICAL MODIFICATION OF A SOLID SURFACE | Micronit Microfluidics B.V. (NL) | 2017-08-23 | — | — | EP | disclosed |
| EP-1363640-B1 | NUCLEIC ACID DERIVATIVES | BIO RAD LABORATORIES (US) | 2010-04-28 | — | — | EP | disclosed |
| US-7683164-B2 | Nucleic acid derivatives | BIO-RAD LABORATORIES INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090005334-A1 | cyclic moieties which enable the formation of stable hybrids with natural nucleic acids and can therefore be efficiently used in a wide variety of applications and, in particular, in antisense therapy | BIO-RAD LABORATORIES INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-1994026738-A1 | N'-HETEROCYCLYL-N-BENZOFURANYL UREA DERIVATIVES AND THEIR ANALOGS AS ACAT INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005334-A1 | cyclic moieties which enable the formation of stable hybrids with natural nucleic acids and can therefore be efficiently used in a wide variety of applications and, in particular, in antisense therapy | POLRMT, NSUN2, RNGTT | ALDH1A1 2920/4885SMN1; SMN2 330/4885POLB 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.